Microba Life SciencesASX:MAP -2.50% EBIT per Share is A$-0.04 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, Microba Life Sciences ranks worse than 57.14% on this metric.
Microba Life Sciences's EBIT per Share for the
six
months ended in Dec. 2025 was A$-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.04.
During the past 3 years, the average EBIT per Share Growth Rate was 7.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Microba Life Sciences's EBIT per Share or its related term are showing as below:
ASX:MAP'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 7.3 Med: 7.3 Max: 7.3
Current: 7.3
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Microba Life Sciences was 7.30% per year. The lowest was 7.30% per year. And the median was 7.30% per year.
ASX:MAP's 3-Year EBIT Growth Rate is ranked worse than 57.14% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75
vs ASX:MAP: 7.30
Microba Life Sciences (ASX:MAP) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Microba Life Sciences EBIT per Share Related Terms
Microba Life Sciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences (ASX:MAP) has a EBIT per Share of A$-0.04 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Microba Life Sciences and its competitors. According to the industry distribution chart, Microba Life Sciences ranks #96 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 57.1%.
Is Microba Life Sciences' EBIT per Share too high?
Microba Life Sciences' current EBIT per Share is A$-0.04. Based on the distribution chart, Microba Life Sciences ranks #96 out of 168 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Microba Life Sciences' EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #96 out of 168 companies for EBIT per Share. This places Microba Life Sciences in the lower half of its industry. The industry median EBIT per Share is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current EBIT per Share is A$-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84.4% below its estimated fair value. The current EBIT per Share is A$-0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current EBIT per Share is A$-0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 